Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.4 USD | +0.59% | -4.31% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15M | Capitalization | 385M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 99.6M | Net cash position 2025 * | 53.37M | EV / Sales 2025 * | 22.1 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.81% |
1 day | +0.59% | ||
1 week | -4.31% | ||
Current month | -1.73% | ||
1 month | -1.41% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 15.33 | +0.13% | 15 306 |
24-05-15 | 15.31 | -0.97% | 28,648 |
24-05-14 | 15.46 | -0.13% | 34,028 |
24-05-13 | 15.48 | -2.09% | 27,651 |
24-05-10 | 15.81 | -1.31% | 74,968 |
Delayed Quote Nasdaq, May 16, 2024 at 12:47 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 385M | |
+33.07% | 49.46B | |
+2.08% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.08% | 26.61B | |
-22.56% | 18.64B | |
+8.43% | 13.16B | |
+30.32% | 12.55B | |
+24.00% | 12.1B |
- Stock Market
- Equities
- CTNM Stock